^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    AHCYL1 (Adenosylhomocysteinase Like 1)

    i
    Other names: AHCYL1, Adenosylhomocysteinase Like 1, XPVKONA, IRBIT, Inositol 1,4,5-Trisphosphate Receptor-Binding Protein, S-Adenosylhomocysteine Hydrolase-Like Protein 1, Protein Phosphatase 1 Regulatory Subunit 78, IP(3)Rs Binding Protein Released With IP(3), S-Adenosyl-L-Homocysteine Hydrolase 2, Putative Adenosylhomocysteinase 2, DC-Expressed AHCY-Like Molecule, AdoHcyase 2, PPP1R78, DCAL, Dendritic Cell Expressed AHCY-Like Protein, Epididymis Secretory Sperm Binding Protein, S-Adenosyl Homocysteine Hydrolase Homolog, S-Adenosylhomocysteine Hydrolase-Like 1, denosylhomocysteinase-Like 1, Adenosylhomocysteinase 2, PRO0233, AHCYL1
    over1year
    The role of S-adenosylhomocysteine hydrolase-like 1 in cancer. (PubMed, Biochim Biophys Acta Mol Cell Res)
    Understanding the mechanisms regulating the functional interplay between the tumor and the tumor microenvironment that controls the expression of AHCYL1 could provide a deeper comprehension of the regulation of tumor development. Addressing how AHCYL1 modulates cellular plasticity processes in a tumoral context is potentially relevant to developing translational approaches in cancer biology.
    Review • Journal
    |
    AHCYL1 (Adenosylhomocysteinase Like 1)
    over2years
    Concomitant deletion of the short arm (Del 1p13.3) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. (PubMed, Cancer)
    The PFS and OS of patients with combined abnormalities of del (1p13.3)/1q21gain or amp was significantly worse compared to del(1p13.3) alone and 1q21gain or 1q21 amp alone, which identifies a subset of patients with poor clinical outcomes.
    Clinical data • Journal
    |
    AHCYL1 (Adenosylhomocysteinase Like 1)
    |
    C1As
    almost3years
    S-adenosylhomocysteine hydrolase-like protein 1 (AHCYL1) inhibits lung cancer tumorigenesis by regulating cell plasticity. (PubMed, Biol Direct)
    These findings indicate that AHCYL1 is a negative regulator in NSCLC tumorigenesis by modulating cell differentiation state and highlighting AHCYL1 as a potential prognostic biomarker for lung cancer.
    Journal
    |
    POU5F1 (POU Class 5 Homeobox 1) • AHCYL1 (Adenosylhomocysteinase Like 1)
    almost4years
    AHCYL1 Is a Novel Biomarker for Predicting Prognosis and Immunotherapy Response in Colorectal Cancer. (PubMed, J Oncol)
    Finally, a predictive nomogram based on these genes was developed and verified, yielding a C-index of 0.74. For CRC patients, the prognostic model based on AHCYL1 and AHCYL1-related genes showed a high predictive performance in terms of prognosis and immunotherapy response.
    Journal • Tumor Mutational Burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • AHCYL1 (Adenosylhomocysteinase Like 1)
    over4years
    Concomitant Deletion of Short Arm (del 1p) and Amplification or Gain (1q21) of Chromosome 1 By Fluorescence in Situ Hybridization (FISH) Is Associated with Poor Clinical Outcome (ASH 2021)
    Concomitant del 1p with 1q21 gain and /or amp was present in 8% of patients. The PFS and OS of patients with combined del1p/1q21gain abnormalities was significantly worse compared to del 1p alone and 1q21 gain alone and thus identifies a subset of patients with poor clinical outcome.
    Clinical • Clinical data
    |
    AHCYL1 (Adenosylhomocysteinase Like 1)
    |
    C1As